FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment
-FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020- -Application supported…
Pharmaceuticals, Biotechnology and Life Sciences
-FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020- -Application supported…
JERUSALEM & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of…
Venom of Australia’s deadliest snake leads to revolutionary serum collection technology MELBOURNE, Australia–(BUSINESS WIRE)–Medical device company Q-Sera Pty Ltd today…
CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #AMD—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies…
Dravet syndrome is a severe and progressive genetic epilepsy generally caused by mutations in the SCN1A gene The BUTTERFLY study…
Pharma industry’s leading enterprise marketplace ranks #30 among health companies SAN DIEGO–(BUSINESS WIRE)–#fasterscience—Inc. magazine today revealed that Scientist.com, the world’s…
– Global clinical trial underway in 11 countries, including U.S., European, and Eastern European sites to evaluate safety, efficacy and…
LONDON–(BUSINESS WIRE)–#Biotechnology–The global Interleukin inhibitors market 2019-2023 is expected to post a CAGR of more than 13% during the period…
— Study will evaluate the safety and preliminary efficacy of AR-13503 SR Implant as monotherapy and in combination with aflibercept…
– SYNB1020 well tolerated in Phase 1b/2a study, but did not lower blood ammonia in patients with cirrhosis – –…